Haemonetics Corporation (NYSE:HAE) Shares Sold by TD Asset Management Inc

TD Asset Management Inc cut its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 46.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,418 shares of the medical instruments supplier's stock after selling 25,802 shares during the quarter. TD Asset Management Inc owned 0.06% of Haemonetics worth $1,870,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HAE. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics in the fourth quarter worth $25,000. Covestor Ltd increased its holdings in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares in the last quarter. KBC Group NV raised its position in shares of Haemonetics by 19.9% during the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock worth $154,000 after acquiring an additional 401 shares during the last quarter. Vise Technologies Inc. raised its position in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock worth $221,000 after acquiring an additional 225 shares in the last quarter. Finally, CWC Advisors LLC. grew its position in Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after purchasing an additional 212 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Price Performance

Shares of HAE traded down $18.61 during trading hours on Thursday, reaching $57.16. 3,464,180 shares of the stock traded hands, compared to its average volume of 757,001. The company has a market cap of $2.75 billion, a P/E ratio of 16.95, a price-to-earnings-growth ratio of 1.23 and a beta of 0.40. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. The company's 50-day moving average price is $73.41 and its two-hundred day moving average price is $67.71. Haemonetics Corporation has a 52-week low of $55.30 and a 52-week high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.08. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. During the same quarter last year, the company posted $1.02 earnings per share. The business's revenue was down 4.4% on a year-over-year basis. On average, analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on HAE shares. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a report on Wednesday, July 9th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. JMP Securities reissued a "market outperform" rating and set a $100.00 price target on shares of Haemonetics in a research note on Tuesday, May 20th. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Raymond James Financial reiterated a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Haemonetics currently has an average rating of "Moderate Buy" and a consensus price target of $95.70.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.